Replimune Group, Inc – a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies – has announced that the US Food and Drug Administration (FDA) has issued a ...
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...
Advisory committee deliberations focused on causal attribution in a single-arm study and whether clinical benefit can be distinguished from nivolumab effect, despite favorable response durability ...
ShopSavvy compares prices across thousands of retailers so you always get the best deal. Prices are updated regularly and verified for accuracy. Our expert reviews and community discussion help you ...
FDA advisory panel votes 10-3 that RP1 trial data show patient benefit Replimune seeks accelerated approval for RP1 with Opdivo in refractory or advanced melanoma FDA decision on RP1 is expected by ...
CTGTAC endorsed that single-arm Ignyte response rate and durability support clinically meaningful systemic antitumor activity attributable to intratumoral RP1 combined with nivolumab in ...
Powered by Sneeze, the first open-source metaverse browser engine under the Metaverse Standards Forum, Artemis introduces metaverse browsing. RP1® today launches Artemis™, the world’s first native ...
The last time I covered Replimune Group, Inc. (REPL), in April this year, discussing the news that the FDA had rejected drug candidate RP1 (vusolimogene oderparepvec) in the indication of anti-PD-1 ...
The FDA has designated the filing as a complete, Class 1 response with a PDUFA target action date of August 2, 2026. The Food and Drug Administration (FDA) has accepted for review Replimune’s ...
Former Senator Ben Sasse speaks about his pancreatic cancer diagnosis and his experience with experimental cancer drugs, the challenges of reforming higher education, the dysfunction in the Senate, ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
For patients whose skin cancer doesn’t respond to traditional treatments, a new drug called RP1 has been a lifeline—at least for those who can get into a clinical trial. The drug has shown so much ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results